Akums Drugs
India's Largest Domestic CDMO
To understand Akums, one must first understand why pharmaceutical companies outsource manufacturing at all. Making medicine is not simply chemistry it is chemistry under surveillance. Every batch must be reproducible. Every facility must satisfy inspectors from the WHO, the US NSF, the European GMP, the UK MHRA, and India’s CDSCO. Every tablet must dissolve at precisely the right rate. Every vial must be sterile, stable, and correctly dosed. This compliance infrastructure costs hundreds of crores to build and years to certify.
Smaller pharmaceutical companies and even large ones pursuing asset-light strategies increasingly find it rational to outsource this complexity to specialists who have already made the investment. Akums is that specialist, at scale. The company operates 14 state-of-the-art manufacturing facilities, producing an extraordinary range of 60+ dosage forms: tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, gummies, and nasal sprays. Its cumulative CDMO formulation capacity stands at 49.6 billion units annually.
Akums operates across three revenue segments. First, the CDMO business the core which contributes approximately 78% of group revenue. Here, Akums manufactures formulations for over 1,400 clients, including 26 of the Top 30 Indian pharmaceutical companies by sales. The client relationship is deeply embedded: once a product is qualified at an Akums facility, switching requires regulatory re-filing and re-audit, creating natural stickiness. Second, the branded formulations business, run through subsidiaries Akumentis (India) and Unosource (70+ export countries), which sells Akums’ own branded and generic products. Third, the API (Active Pharmaceutical Ingredients) business, which manufactures key starting materials primarily cephalosporins and is currently loss-making due to price erosion, but strategically positioned as a supply chain hedge.
A defining characteristic of Akums’ position is the breadth of its intellectual property in manufacturing processes. The company has commercialised 4,146 formulations across 60+ dosage forms since inception. This library of manufacturing know-how, built over 20 years, is not easily replicated.
